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Possible Subclinical Leaflet Thrombosis in Bioprosthetic  
Aortic Valves
To the Editor: Makkar et al. (Nov. 19 issue)1 
report possible subclinical leaflet thrombosis in 
up to 40% of patients involved in a clinical trial 
of transcatheter aortic-valve replacement (TAVR). 
In contrast, we found a relatively low incidence 
(7%) of possible subclinical valve leaflet throm-
bosis among patients in our series in which 
255 patients underwent TAVR with the use of a 
CoreValve prosthesis.
A retrospective review of our series (unpub-
lished data) showed that in 104 patients, cardiac 
computed tomography (CT) at a median of 7 days 
after implantation (range, 3 to 87) (in 51 patients), 
transesophageal echocardiography at a median 
of 45 days (range, 7 to 421) after implantation 
(in 76 patients), or both (in 23 patients) was 
performed. In 101 patients, the findings were 
deemed to be interpretable. Of these patients, 
52% were receiving dual antiplatelet therapy, 19% 
aspirin or thienopyridine monotherapy, and 
29% oral anticoagulation.
A definite thrombus was identified in three 
patients (3%; one patient each on days 31, 44, 
and 87 after implantation). All three patients 
were receiving continuous dual antiplatelet ther-
apy. An additional four patients (4%) had hypo-
attenuated leaflet thickening (two patients on 
day 7 after implantation and one patient each on 
days 8 and 47 after implantation). We hypothe-
size that besides the antithrombotic strategy, the 
valve type (bovine vs. porcine) and design (intra-
annular vs. supraannular) might also be related 
to the occurrence of thrombosis, at least in self-
expandable nitinol frames.
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To the Editor: Makkar et al. describe the phe-
nomenon of reduced leaflet motion in patients 
who had received bioprosthetic aortic valves. An 
in vitro study by Ducci et al.1 showed that TAVR 
produced substantial alteration of the flow pat-
tern in the sinuses of Valsalva, creating regions 
of blood stasis that could lead to thrombus for-
mation. This abnormal condition is not observed 
after conventional surgical aortic-valve replace-
ment because the complete resection of the calci-
fied leaflets allows preservation of the natural 
geometry and vortex dynamics of the aortic root. 
Moreover, with the use of TAVR implants, there 
is often angular or rotational misalignment with 
the sinuses and coronary ostia; this could further 
impair local blood flow.
The data reported by Makkar et al. and Ducci 
et al. suggest that the use of bioprosthetic valves 
per se is not sufficient to guarantee correct leaf-
let dynamics and avoid the need for anticoagula-
tion. This finding may be particularly alarming 
in light of what has been clinically observed 
with surgical bioprostheses.2-4 The data reported 
by Ducci and colleagues need to be taken into 
account when considering the use of TAVR in 
patients who cannot be treated with anticoagu-
lants and in lower-risk patients.
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To the Editor: Makkar et al. found that reduced 
aortic-valve leaflet motion commonly occurred 
after TAVR or surgical aortic-valve replacement, 
probably because of leaflet thrombosis. An analy-
sis of their CT images showed that most leaflets 
with reduced motion were facing the noncoro-
nary sinus of Valsalva. With identification of the 
location of the thrombosed leaflet, we can hy-
pothesize that a mechanism responsible for this 
observation was the lack of coronary-bound 
blood flow in the noncoronary sinus. We have 
previously found that lack of coronary-bound 
blood flow in the noncoronary sinus was associ-
ated with stasis and reduced wall shear stress in 
the sinus1; theoretically, this could have increased 
the risk of thrombosis of the noncoronary leaflet.
Two additional factors that may contribute to 
this observation in TAVR are the misalignment 
of the prosthetic leaflets and the native sinuses 
of Valsalva and the abnormal location of the 
leaflets relative to the aortic annulus. Reduced 
flow in a coronary sinus because of a partially 
occluded coronary artery may also place the leaf-
let at risk for thrombosis. Studies to corroborate 
or refute this hypothesis are lacking.
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To the Editor: Makkar et al. present data de-
scribing subclinical leaflet thrombosis in biopros-
thetic aortic valves. Although this phenomenon 
may be real, the potential link to neurologic 
events is unclear, and the trial shows neither a 
causal nor a temporal link between imaging 
findings and clinical events.
Makkar and colleagues report three total 
strokes (two with reduced leaflet motion and 
one with normal leaflet motion), all of which 
occurred within 24 hours after the index proce-
dure. Attributing these events to findings on CT 
that was performed at a subsequent time point 
(in two of the patients) is problematic. In addi-
tion, “significant” differences in rates of neuro-
logic events were driven by three transient is-
chemic attacks (TIAs), which are difficult to 
adjudicate and probably multifactorial in this 
patient population.
As physicians who care for patients who have 
aortic stenosis, we have concerns that overreac-
tion to these findings may lead to the use of 
aggressive anticoagulation regimens in elderly 
patients who are at high risk for bleeding. Al-
though these findings warrant further study, at 
present the link to clinical events is weak and 
therefore major changes to clinical practice are 
premature.
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The authors reply: We agree with Miljoen et al., 
Colli et al., and Hatoum et al. that the cause of 
leaflet thrombosis may be multifactorial, includ-
ing but not limited to local flow dynamics in the 
aortic root after valve replacement, the anti-
thrombotic strategy, the valve type and design, 
and perhaps implantation techniques. The hypoth-
esis proposed by Hatoum et al. regarding stasis 
in the noncoronary sinus due to lack of coronary 
flow is certainly interesting, but it was not sub-
stantiated in our trial, since we observed this 
finding in multiple leaflets, irrespective of the 
location of the leaflet in relation to the coronary 
artery. Trials to elucidate the relative contribu-
tion of these factors to the pathogenesis of this 
phenomenon are lacking.
Kodali et al. raise a few issues. Multiple stud-
ies have confirmed the presence of subclinical 
leaflet thrombosis in both transcatheter and 
explanted surgical aortic valves.1-4 We agree that 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITA DEGLI STUDI DI PADOVA on November 20, 2016. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 374;16 nejm.org April 21, 20161592
the cause of neurologic events (strokes or TIAs) 
in patients undergoing TAVR, especially in the im-
mediate postprocedural period, is multifactorial. 
Hence, as we noted in our article, any associa-
tion of subclinical leaflet thrombosis with neu-
rologic events is “preliminary and inconclusive.” 
Nonetheless, the significantly increased rate of 
TIAs, all of which occurred late and after CT 
studies, requires further investigation.
Routine anticoagulation in patients after TAVR 
cannot be recommended at present, given the 
high risk of bleeding in the current TAVR popu-
lation and the uncertain clinical significance of 
this finding. However, these findings provide a 
sound rationale for some of the planned trials of 
various antithrombotic regimens after TAVR and 
call into question current guidelines regarding 
dual antiplatelet therapy. The response of the 
Food and Drug Administration — to incorporate 
CT imaging substudies in the upcoming trials of 
TAVR that involve low-risk patients — is appro-
priate. Given the findings of our trial, identifica-
tion of elevated aortic-valve gradients, heart fail-
ure, or thromboembolic events in patients with 
bioprosthetic aortic valves should prompt physi-
cians to consider CT to rule out valve thrombosis.
Colli and colleagues suggest caution in the 
use of TAVR in low-risk patients or those who 
cannot receive anticoagulants without adverse 
effects. The pivotal trials that established the net 
clinical benefit of TAVR involved high-risk pa-
tients who were not the most appropriate candi-
dates for anticoagulation. Although our imaging 
findings are thought provoking, the expansion 
of TAVR should be guided primarily by large 
randomized trials or registries that are focused 
on clinical outcomes and that measure net clini-
cal benefit. Our trial may stimulate further re-
search on antithrombotic strategies after TAVR.
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Ibrutinib for Chronic Lymphocytic Leukemia
To the Editor: It is not surprising that Burger 
et al. (Dec. 17 issue)1 report positive results in 
the Study of Ibrutinib as Initial Therapy for Pa-
tients with Chronic Lymphocytic Leukemia 
(RESONATE-2), a randomized trial of ibrutinib 
versus chlorambucil in older patients with chron-
ic lymphocytic leukemia (CLL). Chlorambucil has 
served as a comparator in trials of bendamus-
tine, alemtuzumab, ofatumumab, and obinutu-
zumab, and longer durations of progression-free 
survival have been reported with each agent.2-5 In 
addition, these trials have shown longer dura-
tions of overall survival with the use of ibrutinib 
and obinutuzumab.1,2
We reviewed our experience in the Connect 
CLL Disease Registry (ClinicalTrials.gov number, 
NCT01081015). This prospective observational 
study, which was conducted from March 2010 
through January 2014, involved 1494 patients 
with CLL in the United States. We observed that 
only 40 of 889 patients with CLL (4.5%) received 
chlorambucil monotherapy as first-line therapy, 
and event-free survival with this agent was infe-
rior to that with all other commonly used first-
line regimens, even after adjustment for the pa-
tient’s age, performance status, and Charlson 
comorbidity index score (hazard ratio for disease 
progression, relapse, or death, 2.7; 95% confi-
dence interval, 1.3 to 3.7; P = 0.008). Because of 
the superiority of alternative first-line regimens 
and the infrequent use of chlorambucil mono-
therapy, we do not think that chlorambucil 
monotherapy should serve as a comparator regi-
men in future studies of CLL.
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